Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Sizheng Steven Zhao; Stephanie R. Harrison; Antoni Chan; Nick Clarke; Charlotte Davis; Joe Eddison; William J. Gregory; Gareth T. Jones; Helena Marzo-Ortega; Daniel J. Murphy; Virinderjit Sandhu; Raj Sengupta; Stefan Siebert; Ben Thompson; Dale Webb; Max Yates; Karl Gaffney

doi:10.1093/rap/rkad039

Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Sizheng Steven Zhao, Stephanie R. Harrison, Antoni Chan, Nick Clarke, Charlotte Davis, Joe Eddison, William J. Gregory, Gareth T. Jones, Helena Marzo-Ortega, Daniel J. Murphy, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Ben Thompson, Dale Webb, Max Yates, Karl Gaffney

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

6 Downloads (Pure)

Abstract

Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

Original language	English
Article number	rkad039
Journal	Rheumatology Advances in Practice
Volume	7
Issue number	2
Early online date	15 May 2023
DOIs	https://doi.org/10.1093/rap/rkad039
Publication status	Published - 2023

Keywords

AS
Axial spondyloarthritis
biologic
biosimilar
IL17
JAK inhibitor
switching
tapering
treat-to-target

Access to Document

10.1093/rap/rkad039Licence: CC BY

rkad039Final published version, 598 KBLicence: CC BY

Cite this

Zhao, S. S., Harrison, S. R., Chan, A., Clarke, N., Davis, C., Eddison, J., Gregory, W. J., Jones, G. T., Marzo-Ortega, H., Murphy, D. J., Sandhu, V., Sengupta, R., Siebert, S., Thompson, B., Webb, D., Yates, M., & Gaffney, K. (2023). Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 7(2), [rkad039]. https://doi.org/10.1093/rap/rkad039

@article{43d7e2cbf0934f61901f898e4e668b8c,

title = "Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope",

abstract = "Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.",

keywords = "AS, Axial spondyloarthritis, biologic, biosimilar, IL17, JAK inhibitor, switching, tapering, treat-to-target",

author = "Zhao, {Sizheng Steven} and Harrison, {Stephanie R.} and Antoni Chan and Nick Clarke and Charlotte Davis and Joe Eddison and Gregory, {William J.} and Jones, {Gareth T.} and Helena Marzo-Ortega and Murphy, {Daniel J.} and Virinderjit Sandhu and Raj Sengupta and Stefan Siebert and Ben Thompson and Dale Webb and Max Yates and Karl Gaffney",

note = "Funding Information: S.S.Z. is supported by a National Institute for Health Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant numbers 21173, 21754 and 21755). H.M.-O. is Chair and Trustee of the British Society for Spondyloarthritis (BRITSpA). H.M.-O. is supported by the NIHR Leeds Biomedical Research Centre (LBRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health.",

year = "2023",

doi = "10.1093/rap/rkad039",

language = "English",

volume = "7",

journal = "Rheumatology Advances in Practice",

issn = "2514-1775",

publisher = "Oxford University Press",

number = "2",

}

Zhao, SS, Harrison, SR, Chan, A, Clarke, N, Davis, C, Eddison, J, Gregory, WJ, Jones, GT, Marzo-Ortega, H, Murphy, DJ, Sandhu, V, Sengupta, R, Siebert, S, Thompson, B, Webb, D, Yates, M & Gaffney, K 2023, 'Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope', Rheumatology Advances in Practice, vol. 7, no. 2, rkad039. https://doi.org/10.1093/rap/rkad039

TY - JOUR

T1 - Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

AU - Zhao, Sizheng Steven

AU - Harrison, Stephanie R.

AU - Chan, Antoni

AU - Clarke, Nick

AU - Davis, Charlotte

AU - Eddison, Joe

AU - Gregory, William J.

AU - Jones, Gareth T.

AU - Marzo-Ortega, Helena

AU - Murphy, Daniel J.

AU - Sandhu, Virinderjit

AU - Sengupta, Raj

AU - Siebert, Stefan

AU - Thompson, Ben

AU - Webb, Dale

AU - Yates, Max

AU - Gaffney, Karl

N1 - Funding Information: S.S.Z. is supported by a National Institute for Health Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant numbers 21173, 21754 and 21755). H.M.-O. is Chair and Trustee of the British Society for Spondyloarthritis (BRITSpA). H.M.-O. is supported by the NIHR Leeds Biomedical Research Centre (LBRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health.

PY - 2023

Y1 - 2023

N2 - Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

AB - Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

KW - AS

KW - Axial spondyloarthritis

KW - biologic

KW - biosimilar

KW - IL17

KW - JAK inhibitor

KW - switching

KW - tapering

KW - treat-to-target

UR - http://www.scopus.com/inward/record.url?scp=85161114437&partnerID=8YFLogxK

U2 - 10.1093/rap/rkad039

DO - 10.1093/rap/rkad039

M3 - Article

AN - SCOPUS:85161114437

VL - 7

JO - Rheumatology Advances in Practice

JF - Rheumatology Advances in Practice

SN - 2514-1775

IS - 2

M1 - rkad039

ER -

Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Abstract

Keywords

Access to Document

Other files and links

Cite this